These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 37921757)

  • 1.
    de Oliveira DF
    J Biomol Struct Dyn; 2023 Nov; ():1-19. PubMed ID: 37921757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating the discovery of the beyond rule of five compounds that have high affinities toward SARS-CoV-2 spike RBD.
    Abu-Saleh AAA; Yadav A; Poirier RA
    J Biomol Struct Dyn; 2023 Apr; 41(6):2518-2527. PubMed ID: 35132950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study.
    Mishra GP; Bhadane RN; Panigrahi D; Amawi HA; Asbhy CR; Tiwari AK
    Comput Biol Med; 2021 Jul; 134():104464. PubMed ID: 34020130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.
    Elzupir AO
    J Biomol Struct Dyn; 2022 Mar; 40(5):2113-2120. PubMed ID: 33094705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA.
    Kumari R; Kumar V; Dhankhar P; Dalal V
    J Biomol Struct Dyn; 2023 Jul; 41(10):4650-4666. PubMed ID: 35510600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
    Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; Brás NF; Jha HC
    J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual Screening of
    Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
    Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
    Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silybin B and Cianidanol Inhibit M
    Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
    Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
    Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
    J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
    Elmaaty AA; Darwish KM; Khattab M; Elhady SS; Salah M; Hamed MIA; Al-Karmalawy AA; Saleh MM
    J Biomol Struct Dyn; 2022; 40(19):8866-8893. PubMed ID: 33928870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An In silico Investigation to Identify Promising Inhibitors for SARS-CoV-2 M
    Alagarsamy V; Sundar PS; Narendhar B; Sulthana MT; Kulkarni VS; Aishwarya AD; Solomon VR; Murugesan S; Jubie S; Rohitha K; Dhanwar S
    Med Chem; 2023; 19(9):925-938. PubMed ID: 37069723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.